title: Biologic product identification and US pharmacovigilance in the biosimilars era.
authors: Amgen Inc., Washington, DC, USA.
authors: Thomas
authors: T
authors: Felix
authors: Amgen Inc., Zug, Switzerland.
authors: Torbjörn T
authors: TT
authors: Johansson
authors: Amgen Inc., Thousand Oaks, California, USA.
authors: Jodi A
authors: JA
authors: Colliatie
authors: Amgen Inc., Thousand Oaks, California, USA.
authors: Michael R
authors: MR
authors: Goldberg
authors: Onyx Pharmaceuticals, UK Limited, Birmingham, UK.
authors: Andrew R
authors: AR
authors: Fox
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D059451:Biosimilar Pharmaceuticals / Q000145:classification / Q000592:standards; D006801:Humans; D061214:Patient Safety; D060735:Pharmacovigilance; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D059451:Biosimilar Pharmaceuticals